Skip to main content

Table 1 Blood parameters and patient demographic measured in CFS/ME patients and NFC groups

From: Rituximab impedes natural killer cell function in Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients: A pilot in vitro investigation

  NFC (n = 9) CFS/ME (n = 8) P value
Age (years) 37.56 ± 11.06 48.63 ± 15.69 0.503
Gender
Male n(%) 3(33.3) 1 (12.5)  
Female n(%) 6 (66.7) 7 (87.5)  
Pathology
White Cell Count (× 109/L) 5.94 ± 1.61 5.45 ± 1.09 0.664
Neutrophils (×109/L) 3.54 ± 1.49 3.36 ± 0.82 0.847
Lymphocytes (× 109/L) 1.87 ± 0.38 1.70 ± 0.49 0.248
Monocytes (× 109/L) 0.32 ± 0.11 0.32 ± 0.06 0.962
Eosinophils (× 109/L) 0.18 ± 0.09 0.18 ± 0.12 0.885
Platelet (× 109/L) 240.78 ± 47.65 258.88 ± 37.13 0.413
Haemoglobin (g/L) 132.67 ± 8.51 135.38 ± 7.82 0.384
Haematocrit 0.37 ± 0.10 0.42 ± 0.03 0.191
Red Cell Count (× 1012/L) 4.53 ± 0.34 4.49 ± 0.34 0.923
MCV fl 89.67 ± 2.74 92.88 ± 5.11 0.222
  1. Results from white and red blood cell parameters measured in CFS/ME and control groups. Comparisons of blood parameters between the CFS/ME and NFC revealed no significant differences. No significant differences were observed in patient age distribution. Data presented as mean ± standard deviation. Abbreviations: NFC, non-fatigued controls; CFS/ME, chronic fatigue syndrome; ME, Myalgic encephalomyelitis